Pelthos Therapeutics Inc. (PTHS) Stock Price
PTHSStock
$20.15−24.89%52W
Market Cap$77.14M
P/E—
PEG Ratio—
Div yield—
Beta3.14
PTHS Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-22.30%
Price vs S&P 500 (4W)-11.63%
VGM Score55.20
PTHS Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$2.95 | -$3.79 | -28.63%(-$0.84) | |
| Q1 2026 | -$3.58 | -$4.66 | -30.24%(-$1.08) | |
| Q4 2025 | -$4.18 | -$2.69 | +35.83%(+$1.50) | |
| Q3 2025 | -$0.57 | -$5.30 | -821.74%(-$4.73) | |
| Q2 2025 | -$6.26 | -$5.38 | +14.06%(+$0.88) |
PTHS Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.15
4.15
4.15
4.15
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
PTHSPelthos Therapeutics Inc. | — | — | C | 1.8x | — | 78.6% | — | $20.15 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
About Pelthos Therapeutics Inc.
Pelthos Therapeutics is a clinical-stage biotechnology company developing non-opioid pain therapeutics by targeting the NaV1.7 sodium ion channel. The company's pipeline focuses on treating chronic visceral pain, acute and chronic eye pain, and post-surgical nerve pain. Lead candidates include CC8464 and CT2000, with CT2000 specifically targeting acute and chronic dry eye disease.